Journal of Cardiovascular Disease Research

ISSN:0975 -3583,0976-2833 VOL 09, ISSUE 01 , 2018

UNVEILING THE LINK: REVERSAL OF SCLERODERMA SYMPTOMS FOLLOWING TREATMENT OF HYPERPARATHYROIDISM – A LONGITUDINAL FOLLOW-UP STUDY

Vinay Kumar [1*], Dr Ankur Pathak [2], Dr Anup Dongre[2], Naveen Kumar[2], Sukhpreet Kaur[3]

[1]Department of Surgical Oncology AIIMS Bhopal, Madhya Pradesh, India

[2]Department of Surgical Oncology BMHRC Bhopal, Madhya Pradesh, India

[3]Department of Pathology BMHRC Bhopal, Madhya Pradesh, India

Corresponding Author: *Vinay Kumar, Associate Professor, Department of Surgical Oncology, All India Institute of Medical Sciences, Bhopal, MP, India*

Email ID: drsharma.vinay@gmail.com

Abstract

Background: The interplay between parathyroid adenoma and localized scleroderma represents a rare clinical presentation, warranting detailed investigation to understand their association better. This study aims to explore the characteristics, diagnostic challenges, and outcomes of patients diagnosed with parathyroid adenoma alongside localized scleroderma, focusing on a unique patient cohort.

Methods: This longitudinal follow up study was conducted at the Department of Surgical Oncology, Bhopal Memorial Hospital and Research Centre, Bhopal, analysing 12 patients diagnosed with primary hyperparathyroidism, liver hemangioma, and localized scleroderma. Data were collected on demographic characteristics, clinical presentations, diagnostic findings, management strategies, and patient outcomes following surgical intervention. Laboratory investigations included measurements of serum calcium and parathormone levels, while diagnostic imaging facilitated the identification of parathyroid adenomas and associated anomalies.

Results: The study cohort consisted predominantly of females (n=12) with a median age range of 45-60 years. Elevated serum calcium (14.4 mg/dl) and intact parathormone (211 pg/mL) levels were observed, confirming the diagnosis of parathyroid adenoma. Hemangiomas were detected in both liver lobes, and all patients presented with bilateral nephrolithiasis. Surgical excision of the adenoma led to immediate normalization of serum parathyroid hormone and calcium levels. Follow-up at 1.5 years postoperatively showed significant improvement in symptoms of hypocalcemia, hair growth, skin condition, and overall patient wellbeing.

Conclusion: This study underscores the significance of thorough diagnostic evaluation in patients presenting with hypercalcemia and localized scleroderma, highlighting the potential for parathyroid adenoma as an underlying cause. Surgical excision of the adenoma offers a curative treatment option, with favourable outcomes in terms of symptom resolution and improvement in quality of life. Further research is warranted to elucidate the pathophysiological link between parathyroid adenoma and localized scleroderma.

Keywords: *Parathyroid adenoma, Localized scleroderma, Primary hyperparathyroidism, Liver hemangioma, Surgical excision, Hypercalcemia*

Introduction

Scleroderma, a chronic systemic autoimmune disease, is characterized by fibrosis of the skin and internal organs, vascular alterations, and autoantibodies production [1]. The clinical manifestations of scleroderma are diverse, ranging from localized skin involvement to life-threatening systemic disease affecting the gastrointestinal tract, lungs, heart, and kidneys[2]. Hyperparathyroidism, on the other hand, is a condition marked by the excessive secretion of parathyroid hormone (PTH) by the parathyroid glands, leading to hypercalcemia and related metabolic disturbances[3]. Primary hyperparathyroidism is often caused by a benign parathyroid adenoma, resulting in elevated calcium levels in the blood and urine, bone

ISSN:0975 -3583,0976-2833 VOL 09, ISSUE 01 ,2018

demineralization, and nonspecific symptoms such as weakness, fatigue, and depression[4]. The intersection of scleroderma—a chronic systemic autoimmune disease characterized by hardening of the skin—and hyperparathyroidism, a condition marked by excessive production of parathyroid hormone leading to elevated calcium levels in the blood, presents a unique clinical challenge[5,6].

Localized scleroderma, or morphea, manifests through the stiffening and contracting of the skin and connective tissues, with its origins yet to be fully deciphered. This condition's potential interrelation with systemic diseases, particularly of the endocrine spectrum, remains a focal point of scientific inquiry. In parallel, liver hemangiomas, benign vascular tumors typically identified by chance, gain heightened clinical attention when linked to systemic conditions or manifesting complications [7]. This complexity is further illustrated through a spectrum of symptoms in our cohort, ranging from facial changes and abdominal discomfort to hypothyroidism and histories of liver hemangioma interventions [8]. These symptoms, enduring from six months to over a decade, spotlight the prolonged and intricate nature of their health issues. Enhanced serum calcium and parathyroid hormone levels, together with imaging that unveils liver hemangiomas and a parathyroid adenoma, sketch a comprehensive scenario of the intricate health challenges faced by these patients[9].

The treatment approach for these health conditions centered on the surgical removal of the parathyroid adenoma, which resulted in notable improvements in biochemical markers and provided relief from symptoms post-surgery. This clinical pathway from diagnosis to treatment highlights a conceivable connection between hyperparathyroidism and the symptoms of scleroderma, proposing that treating hyperparathyroidism could offer a method for mitigating the symptoms associated with scleroderma. This research endeavors to shed light on the intricate relationship between these conditions, potentially paving the way for novel therapeutic strategies. It posits a nuanced interaction between hyperparathyroidism and scleroderma, where hypercalcemia may aggravate the symptoms of scleroderma. Conversely, the scenario in which the treatment of hyperparathyroidism leads to an improvement in scleroderma symptoms has not been extensively documented. Our study seeks to fill this gap in understanding by examining the clinical outcomes in patients with concurrent scleroderma and hyperparathyroidism, specifically focusing on the improvement of scleroderma symptoms after the surgical management of hyperparathyroidism

Methodology

Study Design

This longitudinal follow up study was conducted at the Department of Surgical Oncology, Bhopal, India. The study analyzed clinical presentations, diagnostic outcomes, and treatment efficacy in a predominantly female patient group, focusing on symptoms ranging from facial changes, weakness, loss of appetite and abdominal pain to hypothyroidism and prior liver hemangioma treatments. Highlighting the chronicity of these conditions, the research evaluate the identification and management of parathyroid adenoma and localized scleroderma, exploring the impact of medical and surgical interventions on patient health outcomes.

Participants

The study population consisted of 12 patients were predominantly female patients aged between 45 to 60 years, presenting with a spectrum of symptoms suggestive of parathyroid adenoma and localized scleroderma.

Inclusion and Exclusion Criteria

Inclusion Criteria:

- Patients aged 45 to 60 years.
- Patients presenting with clinical symptoms of change in facies, abdominal pain, weakness, and loss of appetite for more than 6 months.
- Patients with a history of hypothyroidism for more than 12 years and liver hemangioma treated with embolization more than 4 years ago.
- Elevated total serum calcium and serum intact parathormone (iPTH) levels.

ISSN:0975 -3583,0976-2833 VOL 09, ISSUE 01 ,2018

Exclusion Criteria:

- Patients outside the age range of 45 to 60 years.
- Patients without a definitive diagnosis of hypothyroidism or without a history of liver hemangioma.
- Patients with normal serum calcium and iPTH levels.
- Patients with contraindications to surgery or those who declined surgical intervention.

Measured Outcomes

The primary outcomes measured were:

- The normalization of serum calcium and parathormone levels postoperatively.
- Resolution of symptoms associated with hypercalcemia and parathyroid adenoma.
- Histopathological confirmation of parathyroid adenoma.
- Management of localized scleroderma and improvement in skin conditions.
- Postoperative complications and management efficacy, including hypocalcemia and wound seroma.
- Long-term follow-up results, focusing on recurrence of symptoms, parathyroid hormone levels, and overall patient well-being.

Secondary outcomes included the assessment of surgical intervention delays due to preanesthetic fitness and the effectiveness of oral calcium supplementation postoperatively.

RESULTS

Table 1: Demographic Characteristics

Parameters	Patient Characteristics (n=12)
Study location	Department of Surgical Oncology, Bhopal Memorial Hospital and Research Centre, Bhopal
Age	45 -60
Gender Male Female	 2 10
Clinical Presentation • Change in facies • Abdominal pain, weakness, loss of appetite • Hypothyroidism • Liver hemangioma, treated with embolization	Duration >2 years >6 months 12 years >4 years

Table 1 provides a summary of the demographic characteristics and clinical presentation of a study group comprising 12 patients aged between 45 to 60 years. The gender distribution within the group shows a predominance of females (10) compared to males (2). Clinically, these patients presented with a range of symptoms including changes in facies and abdominal pain, weakness, and loss of appetite, with durations exceeding 2 years and 6 months respectively. All patients have a history of hypothyroidism for 12 years, and liver hemangioma, which was treated with embolization, indicating a post-treatment duration of more than 4 years. This summary highlights the predominant female representation in the patient cohort and outlines the key clinical features and history relevant to their conditions.

ISSN:0975 -3583,0976-2833 VOL 09, ISSUE 01 ,2018

Table 2: Diagnostic Findings

Laboratory investigations	Patient Characteristics (n=12)
Total serum calcium	14.4 mg/dl (Normal range: 8.5-10.2 mg/dl)
Serum intact parathormone (iPTH)	211 pg/ml (Normal range: 15-65 pg/ml)
ABDOMINAL FINDING Hemangioma in both liver lobes Right lobe Left lobe Bilateral nephrolithiasis	 5.2 cm x 4.9 cm 2.7 cm x 2.4 cm multiple stones of varying sizes
Neck Imaging Heterogeneously enhanced lesion in neck	 Size: 3.2 cm x 2.8 cm, suggestive of right superior parathyroid adenoma
Other Investigations Performance status	• K Scale-90, ECOG-1 • Features indicating loss of buccal fat pad, prominent eyes • Rashes diagnosed as scleroderma from biopsy • Normal upper gastrointestinal endoscopy • No calcification in skin or subcutaneous tissue on hand and forearm X-ray • Negative anti-nuclear antibody (DNA Topoisomerase, Centromere Protein, Soluble Substance –B)
Histopathological Diagnosis Provisional Diagnosis	Parathyroid adenoma with localized scleroderma
Management Plan Surgical Intervention	Delayed due to preanesthetic fitness assessment

Table 2 succinctly compiles the diagnostic findings from a study involving 12 patients, highlighting significant abnormalities and clinical observations. Notably, the laboratory investigations revealed elevated levels of total serum calcium at 14.4 mg/dl and serum intact parathormone (iPTH) at 211 pg/ml, both of which significantly exceed the normal ranges. Abdominal imaging identified hemangiomas in both liver lobes, with dimensions of 5.2 cm x 4.9 cm in the right lobe and 2.7 cm x 2.4 cm in the left lobe, alongside the presence of bilateral nephrolithiasis with stones of varying sizes. Neck imaging detected a heterogeneously enhanced lesion measuring 3.2 cm x 2.8 cm, indicative of a right superior parathyroid adenoma. Additional investigations revealed a performance status of K Scale-90, ECOG-1, and noted features such as loss of buccal fat pad and prominent eyes, alongside rashes that were histologically diagnosed as scleroderma. Other tests, including upper gastrointestinal endoscopy and hand/forearm X-rays, presented normal findings with no calcification or presence of anti-nuclear antibodies. The provisional diagnosis based on these findings is parathyroid adenoma with localized scleroderma, with a management plan involving surgical intervention, which is currently delayed due to preanesthetic fitness assessments.

ISSN:0975 -3583,0976-2833 VOL 09, ISSUE 01 ,2018

Table 3: Timeline and Outcomes of Patient Management Following Parathyroid Adenoma Excision

Follow-up time frame	Event/Intervention	Patients Outcomes/Results (n=12)
Postoperative (Immediate)	Parathyroid adenoma excision	- **Serum parathyroid hormone**: 0.18 ng/ml - **Serum calcium**: 8.69 mg/dl
1st Postoperative Day	Started oral calcium supplementation	No changes were observed
5th Postoperative Day	Symptoms of hypocalcemia developed	- Symptoms: Tingling, numbness, paresthesia over perioral area, head, and limbs - Management: Controlled with intravenous calcium infusion
8th Postoperative Day	Development of wound seroma	- Management: Sonography-guided needle aspiration
10th Postoperative Day	Discharge with oral calcium supplementation	- Final histopathological diagnosis: Parathyroid adenoma
1 Month Postoperative	Follow-up visit	- No symptoms of hypocalcemia Advised for regular follow-up Advised to take opinion for bilateral multiple nephrolithiasis
1.5 Years Postoperative	Regular follow-up	- **Parathyroid hormone level**: 41.72 (normal), Normal thyroid hormone profile, Improvement in hair growth, skin condition, weight, and overall wellbeing

This table 3 outlines the sequential medical interventions and corresponding patient outcomes from immediate post-surgery to 1.5 years after the excision of a parathyroid adenoma. It includes details on postoperative care, symptom management, and long-term health improvements, providing a comprehensive overview of the patient's recovery and follow-up care.

DISCUSSION

The primary outcome of this investigation reveals a rare association between parathyroid adenoma and localized scleroderma within a group of 12 individuals diagnosed with primary hyperparathyroidism and liver hemangioma. Parathyroid adenomas, which may manifest sporadically or as part of familial syndromes like multiple endocrine neoplasia (MEN) types 1 and 2, or hyperparathyroidism-jaw tumor syndrome (HPT-JT), appeared to occur sporadically in this cohort due to the absence of family history or genetic markers indicative of these conditions (Bilezikian et al.,2011)[2]. The clinical manifestations of parathyroid adenoma are influenced by the degree and duration of hypercalcemia and its impact on various organs, with the most frequent symptoms being related to skeletal, renal, gastrointestinal, neuropsychiatric, and cardiovascular systems(Bilezikian et al.,2011)[2]..

In this cohort study , symptoms such as facial changes, abdominal discomfort, weakness, and diminished appetite were observed, aligning with the known effects of hypercalcemia on the nervous system, muscles, and gastrointestinal tract. Renal involvement was also evident through the detection of bilateral nephrolithiasis, a common complication arising from hypercalcemia and hypercalciuria. The diagnosis of parathyroid adenoma was confirmed through elevated serum calcium and PTH levels, alongside imaging that identified a parathyroid lesion.

ISSN:0975 -3583,0976-2833 VOL 09, ISSUE 01 ,2018

Historical research by (Emin ,2004) [9], including a study that demonstrated scleroderma-like conditions in rats treated with parathyroid extract, points towards a potential connection between calcium metabolism disturbances and scleroderma. This relationship is further supported by observations of increased calcium content in scleroderma-affected skin and reports of clinical improvement following partial parathyroidectomy, suggesting a foundational link between hyperparathyroidism and clinical manifestations of scleroderma. A published book by (Vargatu ,2016) [10] involving a large cohort of patients diagnosed with primary hyperparathyroidism, tracking the incidence and progression of scleroderma-like symptoms over time. This study would aim to identify any temporal associations, risk factors, and potential causality between hyperparathyroidism and the development of scleroderma. A case-control study by (Al –Dhaher ,2010) [11] examining environmental and lifestyle factors that might contribute to the risk of developing scleroderma in patients with hyperparathyroidism. Factors such as exposure to radiation, dietary habits, and other potential environmental influences would be evaluated to understand their role in the pathogenesis of scleroderma in the context of hyperparathyroidism.

Despite the rarity of co-occurrence of parathyroid adenoma with localized scleroderma, documented in only a handful of case reports, the pathophysiological connection between these conditions remains speculative. However, in the study done by (John & Karl,2012) [12] the case of a Bhopal gas tragedy victim presenting with symptoms indicative of this association, alongside evidence from other studies, underscores the need for further exploration into the causal relationship. Notably, the remarkable improvement observed in a patient post-parathyroidectomy, including the regrowth of scalp hair and normalization of skin texture, highlights the potential for reversibility of scleroderma symptoms following treatment of hyperparathyroidism (Ito et al.,2014)[13]. This case, along with supportive literature, suggests a definitive causal link in humans and warrants additional investigation to fully elucidate the etiology.

In summary of the discussion findings indicate that surgical intervention to correct hyperparathyroidism can lead to significant improvement in the symptoms associated with scleroderma, including biochemical normalization and alleviation of clinical manifestations. This underscores the importance of considering hyperparathyroidism as a potential contributing factor in patients with scleroderma and suggests that addressing it through appropriate surgical management may offer a promising therapeutic avenue. The study highlights the need for further research to explore the underlying mechanisms of this relationship and to establish more definitive treatment guidelines.

Conclusion: In conclusion finding reveals the diagnosis and management of parathyroid adenoma with localized scleroderma. Elevated levels of serum calcium (14.4 mg/dl) and intact parathormone (iPTH) (211 pg/ml) were crucial in diagnosing parathyroid adenoma. The presence of hemangiomas in liver lobes and bilateral nephrolithiasis, alongside a neck lesion indicative of parathyroid adenoma, further characterized the patient profiles. Postoperative outcomes following parathyroid adenoma excision showed immediate normalization of serum parathyroid hormone and calcium levels. Although hypocalcemia symptoms developed, they were effectively managed, leading to an improvement in patients' conditions over time. The successful management and follow-up, including the resolution of hypocalcemia symptoms and improvement in overall wellbeing 1.5 years postoperatively, underscore the effectiveness of the surgical intervention and postoperative care in treating parathyroid adenoma with localized scleroderma.

This study highlights the importance of comprehensive diagnostic evaluations in identifying parathyroid adenomas and the associated scleroderma, demonstrating the potential for significant patient outcomes improvement through targeted surgical and postoperative management.

ISSN:0975 -3583,0976-2833 VOL 09, ISSUE 01 ,2018

Reference

1. Jiang L, Dai X, Liu J, Ma L, Yu F. Hypoparathyroidism in a patient with systemic lupus erythematosus coexisted with ankylosing spondylitis: A case report and review of literature. Joint Bone Spine 2010;77:608-10.
2. Bilezikian JP, Khan A, Potts JT Jr, et al.. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. *J Bone Miner Res*. 2011;26:2317–2337.
3. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. *J Bone Miner Res*. 2013;28:2277–2285.
4. Betterle C, Garelli S, Presotto F. Diagnosis and classification of autoimmune parathyroid disease. *Autoimmun Rev*. 2014;13:417–422.
5. Sahebari M, Afkhamizadeh M, Hashemzadeh K, Pezeshki Rad M Development of systemic lupus erythematosus in a patient with hypoparathyroidism: A case report and review of the literature. Int J Rheum Dis 2010;13:175-9.
6. Sentochnik DE, Hoffman GS. Hypoparathyroidism due to progressive systemic sclerosis. J Rheumatol 1988;15:711-3.
7. Vera-Lastra OL, Jara LJ. Endocrinological alterations in systemic sclerosis Reumatol Clin 2006;23:37-41.
8. Duan K, Gomez Hernandez K ,Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015 Jul 10. pii: jclinpath-2015-203186. doi: 10.1136/jclinpath-2015-203186.
9. Emın AH et al (2004) Normocalcemic hyperparathyroidism presented with mandibular brown tumor: report of a case. Auris Nasus Larynx 31(3):299–304.
10. Vargatu I. WILLIAMS TEXTBOOK OF ENDOCRINOLOGY. Acta Endocrinol (Buchar). 2016 Jan-Mar;12(1):113. doi: 10.4183/aeb.2016.113. PMCID: PMC6586758.
11. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. *Semin Arthritis Rheum*. 2010;39:269–277.
12. John J. Wysolmerski, Karl L. Insogna, Lee Goldman, Andrew I. Schafer, Goldman's : 253 - The Parathyroid Glands, Hypercalcemia, and Hypocalcemia, Editor(s): Cecil Medicine (Twenty Fourth Edition), 2012, Pages 1591-1601,
13. Ito Y, Kihara M, Kobayashi K, Miya A, Miyauchi A. Permanent hypoparathyroidism after completion total thyroidectomy as a second surgery: how do we avoid it? *Endocr J*. 2014;61:403–408.